Levi & Korsinsky, LLP Announces Class Action Lawsuit against Trubion Pharmaceuticals, Inc. and Its Board of Directors
06 October 2010 - 2:46AM
Business Wire
Levi & Korsinsky, LLP announces that on October 4, 2010,
they filed a class action complaint on behalf of all current
stockholders of Trubion Pharmaceuticals, Inc. (“Trubion”) (NASDAQ:
TRBN) in connection with Trubion’s attempt to merge with Emergent
BioSolutions Inc. (“Emergent”) (NYSE: EBS). The complaint charges
Trubion and Trubion’s board of directors with, among other things,
violations of the Securities Exchange Act of 1934 and Rule 14a-9.
In particular, the complaint alleges that the defendants have
issued materially false and misleading statements regarding the
proposed transaction wherein Trubion intends to merge with
Emergent.
If you wish to serve as lead plaintiff, you must move the Court
no later than 60 days from today. If you wish to discuss this
action or have any questions concerning this notice or your rights
or interests, please contact plaintiffs’ counsel, Eduard Korsinsky,
at Levi & Korsinsky, LLP, (212) 363-7500 or, or via e-mail at
ek@zlk.com. If you are a member of this class, you can view a copy
of the complaint as filed or join this class action online at
http://www.zlk.com. Any member of the putative class may move the
Court to serve as lead plaintiff through counsel of their choice or
may choose to do nothing and remain an absent class member.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A
CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU
RETAIN ONE. AT THIS TIME YOU MAY DO NOTHING AND REMAIN AN ABSENT
CLASS MEMBER. YOU MAY ALSO RETAIN COUNSEL OF YOUR CHOICE.
Levi & Korsinsky, LLP is a national law firm that represents
the rights of shareholders and victims of corporate abuse. We are
headquartered in New York City and have offices in Los Angeles,
California and New Jersey. With over 50 years of combined
litigation experience, the members of L|K have been involved in
hundreds of class action lawsuits and have obtained multi-million
dollar recoveries. L|K has been appointed lead counsel or has
played a major role on behalf of shareholders in a majority of the
merger-related lawsuits that have been filed on behalf of
shareholders throughout the country. The firm has therefore
developed a specialization of knowledge in shareholder rights and
fiduciary duty law.
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Trubion Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More Levi & Korsinsky, LLP News Articles